Kaitai Capital
Finance · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
no.107 Dazifumiaoqian, Hangzhou, ChinaWebsite
www.kaitaicapital.comRevenue
$5.2 MillionIndustry
About Kaitai Capital
Kaitai Capital Org Chart
Is Kaitai Capital your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Kaitai Capital had a recent Job posting/layoffs
Kaitai Capital, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Kaitai Capital launches new products
Earning: See what the market has to say on Kaitai Capital recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Kaitai Capital has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Kaitai Capital
Funding: Get notified immidiatlly once Kaitai Capital has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Kaitai Capital is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Kaitai Capital as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Kaitai Capital is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Kaitai Capital is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Kaitai Capital.
Kaitai Capital Tech Stack
A closer look at the technologies used by Kaitai Capital
Most Recent Scoops
Kaitai Capital News & Media
MingSight Completes a New Round of Financing to Accelerate Clinical Development in Chronic Lymphocytic Leukemia and Diabetic Macular Edema
SAN DIEGO--(BUSINESS WIRE)--MingSight Pharmaceuticals announced today the close of a pre-Series B round of $20M, led by Kaitai Capital. The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PKC) beta for the treatment of Chronic lymphocytic Leukemia (CLL) and Diabetic Macular Edema (DME). “We greatly appreciate the trust and support of our investors,” said Kai Zhang, MD, MBA, CEO and Co-founder of MingSight. “This investment
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Kaitai Capital
凯泰资本 is a venture capital management firm focused on innovative investment management. The company aims to empower entrepreneurs and create value for investors by exploring the essence of change in uncertain trends. Their investment areas include life sciences, artificial intelligence, and digital industries, emphasizing disruptive innovation and v... Read More